Report of the 'Mechanisms of lung injury and immunomodulator interventions in influenza' workshop, 21 March 2010, Ventura, California, USA

Influenza and other Respiratory Viruses

Volumn 5, Issue 6, 2011, Pages

  Howard, Wendy A ^a,b   Peiris, Malik ^c   Hayden, Frederick G ^a,d  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b VETERINARY LABORATORIES AGENCY   (United Kingdom)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 487; ANTIVIRUS AGENT; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CD200 ANTIGEN; CD200 RECEPTOR AGONIST; CELECOXIB; CHEMOKINE RECEPTOR CXCR3; CLARA CELL PROTEIN; CYCLOOXYGENASE 2; GEMFIBROZIL; HILTONOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 22; MESALAZINE; MITOGEN ACTIVATED PROTEIN KINASE P38; OX40 IMMUNOGLOBULIN; OX40 LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RECOMBINANT CC10; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 1; VERY LATE ACTIVATION ANTIGEN 2; VIRUS ANTIGEN; ZANAMIVIR;

2009 H1N1 INFLUENZA; ACUTE CORONARY SYNDROME; ADULT RESPIRATORY DISTRESS SYNDROME; ANTHRAX; ANTIGEN DETECTION; ARTICLE; BACTERIAL INFECTION; BODY MASS; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; ENTERITIS; ENZYME INDUCTION; ENZYME POLYMORPHISM; HEREDITY; HERPES SIMPLEX; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; INFECTION RATE; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A (H5N1); INJURY SEVERITY; KNOCKOUT MOUSE; LUNG EDEMA; LUNG INJURY; LYMPHOCYTOPENIA; MOLECULAR BIOLOGY; MULTIPLE ORGAN FAILURE; NONHUMAN; OBESITY; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOSPHOLIPID METABOLISM; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY FAILURE; SEVERE ACUTE RESPIRATORY SYNDROME; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; VACCINIA; VIRAL CLEARANCE; VIRUS PNEUMONIA; VIRUS REPLICATION;

EID: 80054791083     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2011.00278.x     Document Type: Article

References (131)

1. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261-273.
2. Bautista E, Chotpitayasunondh T, Gao Z et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:1708-1719.
3. Kandun IN, Tresnaningsih E, Purba WH et al. Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet 2008; 372:744-749.
4. Chan PA, Connell NT, Gabonay AM et al. Oseltamivir resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient. Clin Microbiol Infect 2010; 16:1576-1578.
5. Beigel JH, Farrar J, Han AM et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353:1374-1385.
6. Wu JT, Ma ES, Lee CK et al. The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin Infect Dis 2010; 51:1184-1191.
7. Tsai TP, Pedotti P, Hilbert A et al. Regional and age-specific patterns of pandemic H1N1 influenza virus seroprevalence inferred from vaccine clinical trials, August-October 2009. Euro Surveill 2010; 15:pii=19624.
8. Peiris JS, Cheung CY, Leung CY, Nicholls JM. Innate immune responses to influenza A H5N1: friend or foe? Trends Immunol 2009; 30:574-584.
9. de Jong MD, Simmons CP, Thanh TT et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203-1207.
10. Baskin CR, Bielefeldt-Ohmann H, Tumpey TM et al. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci U S A 2009; 106:3455-3460.
11. Shieh WJ, Blau DM, Denison AM et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol 2010; 177:166-175.
12. Cameron CM, Bermejo-Martin JF, Ran L et al. Gene expression analysis of host innate immune responses during Lethal H5N1 infection in ferrets. J Virol 2008; 82:11308-11317.
13. Lee SM, Cheung CY, Nicholls JM et al. Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection. J Infect Dis 2008; 198:525-535.
14. Cheung CY, Poon LL, Lau AS et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002; 360:1831-1837.
15. Perrone LA, Plowden JK, Garcia-Sastre A, Katz JM, Tumpey TM. H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog 2008; 4:e1000115.
16. Lee DC, Cheung CY, Law AH, Mok CK, Peiris M, Lau AS. p38 mitogen-activated protein kinase-dependent hyperinduction of tumor necrosis factor alpha expression in response to avian influenza virus H5N1. J Virol 2005; 79:10147-10154.
17. Hui KP, Lee SM, Cheung CY et al. Induction of proinflammatory cytokines in primary human macrophages by influenza A virus (H5N1) is selectively regulated by IFN regulatory factor 3 and p38 MAPK. J Immunol 2009; 182:1088-1098.
18. Lee SM, Gardy JL, Cheung CY et al. Systems-level comparison of host-responses elicited by avian H5N1 and seasonal H1N1 influenza viruses in primary human macrophages. PLoS ONE 2009; 4:e8072.
19. Chan MC, Cheung CY, Chui WH et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 2005; 6:135.
20. Chan MC, Chan RW, Yu WC et al. Influenza H5N1 virus infection of polarized human alveolar epithelial cells and lung microvascular endothelial cells. Respir Res 2009; 10:102.
21. Mok KP, Wong CH, Cheung CY et al. Viral genetic determinants of H5N1 influenza viruses that contribute to cytokine dysregulation. J Infect Dis 2009; 200:1104-1112.
22. Shapira SD, Gat-Viks I, Shum BO et al. A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection. Cell 2009; 139:1255-1267.
23. Cowling BJ, Chan KH, Fang VJ et al. Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med 2010; 362:2175-2184.
24. Witkop CT, Duffy MR, Macias EA et al. Novel Influenza A (H1N1) outbreak at the U.S. Air Force Academy: epidemiology and viral shedding duration. Am J Prev Med 2010; 38:121-126.
25. Ling LM, Chow AL, Lye DC et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis 2010; 50:963-969.
26. Lee N. Presented at XIIth International Symposium on Respiratory Viral Infections. Taipei, Taiwan, March 2010.
27. Munster VJ, de Wit E, van den Brand JM et al. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 2009; 325:481-483.
28. Maines TR, Jayaraman A, Belser JA et al. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 2009; 325:484-487.
29. Zhang J, Zhang Z, Fan X et al. 2009 pandemic H1N1 influenza virus replicates in human lung tissues. J Infect Dis 2010; 201:1522-1526.
30. Chan MC, Chan RW, Yu WC et al. Tropism and innate host responses of the 2009 pandemic H1N1 influenza virus in ex vivo and in vitro cultures of human conjunctiva and respiratory tract. Am J Pathol 2010; 176:1828-1840.
31. Woo PC, Tung ET, Chan KH, Lau CC, Lau SK, Yuen KY. Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: implications for treatment strategies. J Infect Dis 2010; 201:346-353.
32. Osterlund P, Pirhonen J, Ikonen N et al. Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons. J Virol 2010; 84:1414-1422.
33. Lee SM, Chan RW, Gardy JL et al. Systems-level comparison of host responses induced by pandemic and seasonal influenza A H1N1 viruses in primary human type I-like alveolar epithelial cells in vitro. Respir Res 2010; 11:147.
34. Gill JR, Sheng ZM, Ely SF et al. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med 2010; 134:235-243.
35. Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annu Rev Pathol 2008; 3:499-522.
36. Franks TJ, Chong PY, Chui P et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Hum Pathol 2003; 34:743-748.
37. Herfst S, van den Brand JM, Schrauwen EJ et al. Pandemic 2009 H1N1 Influenza Virus Causes Diffuse Alveolar Damage in Cynomolgus Macaques. Vet Pathol 2010; 47:1040-1047.
38. Mauad T, Hajjar LA, Callegari GD et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med 2010; 181:72-79.
39. Vaillant L, La Ruche G, Tarantola A, Barboza P. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill 2009;14:pii: 19309.
40. Tsatsanis C, Margioris AN, Kontoyiannis DP. Association between H1N1 infection severity and obesity-adiponectin as a potential etiologic factor. J Infect Dis 2010; 202:459-460.
41. Harton JA, Linhoff MW, Zhang J, Ting JP. Cutting edge: CATERPILLER: a large family of mammalian genes containing CARD, pyrin, nucleotide-binding, and leucine-rich repeat domains. J Immunol 2002; 169:4088-4093.
42. Ting JP, Davis BK. CATERPILLER: a novel gene family important in immunity, cell death, and diseases. Annu Rev Immunol 2005; 23:387-414.
43. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20:319-325.
44. Allen IC, Scull MA, Moore CB et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 2009; 30:556-565.
45. Lai KY, Ng WY, Osburga Chan PK, Wong KF, Cheng F. High-dose N-acetylcysteine therapy for novel H1N1 influenza pneumonia. Ann Intern Med 2010; 152:687-688.
46. Richter M, Ray SJ, Chapman TJ et al. Collagen distribution and expression of collagen-binding alpha1beta1 (VLA-1) and alpha2beta1 (VLA-2) integrins on CD4 and CD8 T cells during influenza infection. J Immunol 2007; 178:4506-4516.
47. Chapman TJ, Topham DJ. Identification of a unique population of tissue-memory CD4+ T cells in the airways after influenza infection that is dependent on the integrin VLA-1. J Immunol 2010; 184:3841-3849.
48. Guo H, Topham DJ. Interleukin-22 (IL-22) production by pulmonary Natural Killer cells and the potential role of IL-22 during primary influenza virus infection. J Virol 2010; 84:7750-7759.
49. Konig R, Stertz S, Zhou Y et al. Human host factors required for influenza virus replication. Nature 2010; 463:813-817.
50. Brass AL, Huang IC, Benita Y et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 2009; 139:1243-1254.
51. Hao L, Sakurai A, Watanabe T et al. Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 2008; 454:890-893.
52. Karlas A, Machuy N, Shin Y et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 2010; 463:818-822.
53. Ludwig S. Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. J Antimicrob Chemother 2009; 64:1-4.
54. Schmolke M, Viemann D, Roth J, Ludwig S. Essential impact of NF-kappaB signaling on the H5N1 influenza A virus-induced transcriptome. J Immunol 2009; 183:5180-5189.
55. Mazur I, Wurzer WJ, Ehrhardt C et al. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cell Microbiol 2007; 9:1683-1694.
56. Wang J, Oberley-Deegan R, Wang S et al. Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-lambda 1) in response to influenza A infection. J Immunol 2009; 182:1296-1304.
57. Gardai SJ, Xiao YQ, Dickinson M et al. By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell 2003; 115:13-23.
58. Hartshorn KL, Webby R, White MR et al. Role of viral hemagglutinin glycosylation in anti-influenza activities of recombinant surfactant protein D. Respir Res 2008; 9:65.
59. Miura TA, Wang J, Holmes KV, Mason RJ. Rat coronaviruses infect rat alveolar type I epithelial cells and induce expression of CXC chemokines. Virology 2007; 369:288-298.
60. Imai Y, Kuba K, Neely GG et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008; 133:235-249.
61. Numata M, Chu HW, Dakhama A, Voelker DR. Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection. Proc Natl Acad Sci USA 2010; 107:320-325.
62. Kurt-Jones EA, Popova L, Kwinn L et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1:398-401.
63. Kash JC, Tumpey TM, Proll SC et al. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 2006; 443:578-581.
64. Kash JC, Basler CF, Garcia-Sastre A et al. Global host immune response: pathogenesis and transcriptional profiling of type A influenza viruses expressing the hemagglutinin and neuraminidase genes from the 1918 pandemic virus. J Virol 2004; 78:9499-9511.
65. Powers KA, Szaszi K, Khadaroo RG et al. Oxidative stress generated by hemorrhagic shock recruits Toll-like receptor 4 to the plasma membrane in macrophages. J Exp Med 2006; 203:1951-1961.
66. Berliner JA, Subbanagounder G, Leitinger N, Watson AD, Vora D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med 2001; 11:142-147.
67. Berliner JA, Watson AD. A role for oxidized phospholipids in atherosclerosis. N Engl J Med 2005; 353:9-11.
68. Furnkranz A, Schober A, Bochkov VN et al. Oxidized phospholipids trigger atherogenic inflammation in murine arteries. Arterioscler Thromb Vasc Biol 2005; 25:633-638.
69. Bochkov VN, Kadl A, Huber J, Gruber F, Binder BR, Leitinger N. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature 2002; 419:77-81.
70. Nonas S, Miller I, Kawkitinarong K et al. Oxidized phospholipids reduce vascular leak and inflammation in rat model of acute lung injury. Am J Respir Crit Care Med 2006; 173:1130-1138.
71. Li W, Moore MJ, Vasilieva N et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426:450-454.
72. Kuba K, Imai Y, Rao S et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005; 11:875-879.
73. Kuba K, Imai Y, Ohto-Nakanishi T, Penninger JM. Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol Ther 2010; 128:119-128.
74. Marshall RP, Webb S, Bellingan GJ et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 2002; 166:646-650.
75. Imai Y, Kuba K, Rao S et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436:112-116.
76. Wissinger E, Goulding J, Hussell T. Immune homeostasis in the respiratory tract and its impact on heterologous infection. Semin Immunol 2009; 21:147-155.
77. Humphreys IR, Walzl G, Edwards L, Rae A, Hill S, Hussell T. A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. J Exp Med 2003; 198:1237-1242.
78. Snelgrove RJ, Goulding J, Didierlaurent AM et al. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol 2008; 9:1074-1083.
79. Didierlaurent A, Goulding J, Patel S et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med 2008; 205:323-329.
80. McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 2002; 186:341-350.
81. Aldridge JR Jr, Moseley CE, Boltz DA et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci USA 2009; 106:5306-5311.
82. Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, Fantozzi R. PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int 2009; 55:496-504.
83. Szretter KJ, Gangappa S, Lu X et al. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J Virol 2007; 81:2736-2744.
84. Mizgerd JP, Lupa MM, Hjoberg J et al. Roles for early response cytokines during Escherichia coli pneumonia revealed by mice with combined deficiencies of all signaling receptors for TNF and IL-1. Am J Physiol Lung Cell Mol Physiol 2004; 286:L1302-L1310.
85. Perrone LA, Szretter KJ, Katz KJ, Mizgerd JM, Tumpey JP. Mice lacking both TNF and IL-1 receptors exhibit reduced lung inflammation and delay in onset of death following infection with a highly virulent H5N1 virus. J Infect Dis 2010; 202:1161-1170.
86. Fritz RS, Hayden FG, Calfee DP et al. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis 1999; 180:586-593.
87. Hayden FG, Treanor JJ, Fritz RS et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282:1240-1246.
88. Zheng BJ, Chan KW, Lin YP et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008; 105:8091-8096.
89. Cinel I, Dellinger RP. Advances in pathogenesis and management of sepsis. Curr Opin Infect Dis 2007; 20:345-352.
90. Carey MA, Bradbury JA, Seubert JM, Langenbach R, Zeldin DC, Germolec DR. Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J Immunol 2005; 175:6878-6884.
91. Budd A, Alleva L, Alsharifi M et al. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother 2007; 51:2965-2968.
92. Fedson DS. Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis 2008; 8:571-576.
93. Fedson DS. Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses 2009; 3:129-142.
94. Wang TS, Deng JC. Molecular and cellular aspects of sepsis-induced immunosuppression. J Mol Med 2008; 86:495-506.
95. Fonarow GC, Wright RS, Spencer FA et al. Effect of statin use within the first 24hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005; 96:611-616.
96. van de Garde EM, Hak E, Souverein PC, Hoes AW, van den Bosch JM, Leufkens HG. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006; 61:957-961.
97. Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007; 27:325-332.
98. Mortensen EM, Pugh MJ, Copeland LA et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008; 31:611-617.
99. Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008; 121:1002-1007.
100. Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, Sorensen HT. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29, 900 patients. Arch Intern Med 2008; 168:2081-2087.
101. Myles PR, Hubbard RB, Gibson JE, Pogson Z, Smith CJ, McKeever TM. The impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort. Pharmacoepidemiol Drug Saf 2009; 18:697-703.
102. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006; 333:999.
103. Dublin S, Jackson ML, Nelson JC, Weiss NS, Larson EB, Jackson LA. Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ 2009; 338:b2137.
104. Kwong JC, Li P, Redelmeier DA. Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. PLoS ONE 2009; 4:e8087.
105. Vandermeer M, Thomas A, Kamimoto L et al. Role of statins in preventing death among patients hospitalized with Lab-confirmed influenza infections (abstract 706). Annu Meet Infect Dis Soc Am 2009; October 30, 2009.
106. Paumelle R, Staels B. Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms. Trends Cardiovasc Med 2008; 18:73-78.
107. InFACT Global H1N1 Collaboration. InFACT: a global critical care research response to H1N1. Lancet 2010; 375:11-13.
108. Clement CG, Evans SE, Evans CM et al. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am J Respir Crit Care Med 2008; 177:1322-1330.
109. Evans SE, Scott BL, Clement CG et al. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol 2010; 42:40-50.
110. Tuvim MJ, Evans SE, Clement CG, Dickey BF, Gilbert BE. Augmented lung inflammation protects against influenza A pneumonia. PLoS ONE 2009; 4:e4176.
111. Singh G, Katyal SL. Clara cells and Clara cell 10 kD protein (CC10). Am J Respir Cell Mol Biol 1997; 17:141-143.
112. Bernard A, Marchandise FX, Depelchin S, Lauwerys R, Sibille Y. Clara cell protein in serum and bronchoalveolar lavage. Eur Respir J 1992; 5:1231-1238.
113. Wang SZ, Rosenberger CL, Bao YX, Stark JM, Harrod KS. Clara cell secretory protein modulates lung inflammatory and immune responses to respiratory syncytial virus infection. J Immunol 2003; 171:1051-1060.
114. Stripp BR, Reynolds SD, Boe IM et al. Clara cell secretory protein deficiency alters Clara cell secretory apparatus and the protein composition of airway lining fluid. Am J Respir Cell Mol Biol 2002; 27:170-178.
115. Levine CR, Gewolb IH, Allen K et al. The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. Pediatr Res 2005; 58:15-21.
116. Nosratabadi AR, Ljungman AG, Lindahl M, Welch R, Pilon A, Tagesson C. Clara cell 10-KDA protein inhibits endotoxin-induced airway contraction in isolated perfused rat lungs. Exp Lung Res 2003; 29:455-473.
117. Wong JP, Christopher ME, Salazar AM et al. Broad-spectrum and virus-specific nucleic acid-based antivirals against influenza. Front Biosci (Schol Ed) 2010; 2:791-800.
118. Wong JP, Christopher ME, Viswanathan S et al. Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine 2009; 27:3481-3483.
119. Boukhvalova MS, Sotomayor TB, Point RC, Pletneva LM, Prince GA, Blanco JC. Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus model. J Interferon Cytokine Res 2010; 30:229-242.
120. Larosa SP. Activated protein C for H1N1 influenza? More work to do! Crit Care 2010; 14:156.
121. Keller TT, van der Sluijs KF, de Kruif MD et al. Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. Circ Res 2006; 99:1261-1269.
122. Schouten M, Sluijs KF, Gerlitz B et al. Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study. Crit Care 2010; 14:R65.
123. Cilloniz C, Shinya K, Peng X et al. Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes. PLoS Pathog 2009; 5:e1000604.
124. Wong HK, Lee CK, Hung IF et al. Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfusion 2010; 50:1967-1971.
125. Hung IF, To KK, Lee CK et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52:447-456.
126. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357:1450-1451.
127. Lu J, Guo Z, Pan X et al. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. Respir Res 2006; 7:43.
128. Hanson BJ, Boon AC, Lim AP, Webb A, Ooi EE, Webby RJ. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 2006; 7:126.
129. Baron S, Isaacs A. Absence of interferon in lungs from fatal cases of influenza. Br Med J 1962; 1:18-20.
130. Agrati C, Gioia C, Lalle E et al. Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J Infect Dis 2010; 202:681-689.
131. Le Goffic R, Balloy V, Lagranderie M et al. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog 2006; 2:e53.